Search

Arcutis Biotherapeutics Inc

Suletud

SektorTervishoid

25.04 0.89

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.72

Max

25.07

Põhinäitajad

By Trading Economics

Sissetulek

26M

15M

Müük

24M

130M

P/E

Sektori keskmine

112.636

57.366

Aktsiakasum

0.11

Kasumimarginaal

11.558

Töötajad

354

EBITDA

23M

17M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+47.58% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

27. okt 2026

Turustatistika

By TradingEconomics

Turukapital

-130M

3.1B

Eelmine avamishind

24.15

Eelmine sulgemishind

25.04

Uudiste sentiment

By Acuity

50%

50%

167 / 340 Pingereas Healthcare

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. aug 2026, 19:36 UTC

News

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

24. aug 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

21. aug 2026, 19:56 UTC

Event

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

20. aug 2026, 19:51 UTC

News

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

19. aug 2026, 19:26 UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

18. aug 2026, 19:56 UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

14. aug 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13. aug 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12. aug 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11. aug 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10. aug 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7. aug 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6. aug 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5. aug 2026, 23:02 UTC

News
Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4. aug 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3. aug 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31. juuli 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30. juuli 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29. juuli 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28. juuli 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

27. juuli 2026, 16:07 UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

24. juuli 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

21. juuli 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

20. juuli 2026, 20:14 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

47.58% tõus

12 kuu keskmine prognoos

Keskmine 36.57 USD  47.58%

Kõrge 40 USD

Madal 34 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

167 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat